SDGRSchrödinger, Inc.

$19.47

The financials

Schrödinger, Inc. by the numbers

Schrödinger, Inc. (SDGR) reported revenue of $59M in Q1 2026 (quarter ended March 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $60M. For the full year FY2025, revenue was $256M (+23% year on year) and net income −$103M. Its largest product in 2026-Q1 was Drug Discovery at $23M, 40% of the disclosed total, just ahead of Hosted Software at 21%.

Schrödinger, Inc. income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$59M$60M−1.6%
Gross profit$30M$31M−5.1%
Operating income−$49M−$51Mn/a
Net income−$60M−$60Mn/a
Diluted EPS−$0.81−$0.82n/a
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Drug Discovery$23M40%
Hosted Software$12M21%
Drug Discovery Services$12M21%
Maintenance$6.7M12%
Professional Services$2.6M4.6%
Oncology Neurology And Immunology Product$700K1.2%
Drug Discovery Contribution$148K0.3%
Contribution$72K0.1%
Software Products And Services$3K0.0%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $56.9M (-54%)
Drug Discovery grew +124% year on yearSoftware Contribution -100% year on year
  • Drug Discovery$22.9MQoQ +70%year on year +124%
  • Hosted Software$12.1MQoQ +4.3%year on year +11%
  • Drug Discovery Services$11.7MQoQ -10%year on year +105%
  • Maintenance$6.7MQoQ -2.4%year on year -2.0%
  • Professional Services$2.6MQoQ +66%year on year +40%
  • Oncology Neurology And Immunology Product$700.0KQoQ -year on year +17%
  • Drug Discovery Contribution$148.0KQoQ -year on year -70%
  • Contribution$72.0KQoQ -year on year -98%
  • Software Products And Services$3.0KQoQ -100%year on year -67%
  • Revenue From Contract With Customer Before Contribution-QoQ -year on year -
  • Software Contribution$0.00QoQ -year on year -100%
Segment sum = 97% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-05, SEC EDGAR